A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)

NCT00874939 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease
Dementia

Interventions

DRUG: MK-0249 7.5 mg
DRUG: MK-0249 25 mg
DRUG: Donepezil 5mg
DRUG: Placebo to MK-0249
DRUG: Placebo to Donepezil

Sponsor

Merck Sharp & Dohme LLC